Trials / Completed
CompletedNCT00108797
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eptacog alfa (activated) | |
| DRUG | Feiba VH |
Timeline
- Start date
- 2001-09-01
- Primary completion
- 2006-02-01
- Completion
- 2006-02-01
- First posted
- 2005-04-19
- Last updated
- 2017-01-12
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00108797. Inclusion in this directory is not an endorsement.